ORMPHealthcare · BiotechnologyORMP Stock Forecast: Oramed Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
ORMP stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Oramed Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (83): The share price has been relatively steady.
Accruals (10): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
ORMP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ORMP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 20 May 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 17 May 2023 | Canaccord Genuity | Maintains | Hold | — |
| 17 Jan 2023 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 12 Jan 2023 | Canaccord Genuity | Downgrade | Hold | — |
| 16 May 2022 | Aegis Capital | Maintains | Buy | — |
| 18 Feb 2022 | Cantor Fitzgerald | Initiates | Overweight | — |
| 30 Nov 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Nov 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Nov 2021 | Aegis Capital | Maintains | Buy | — |
| 29 July 2021 | Canaccord Genuity | Maintains | Buy | — |
| 8 June 2021 | Aegis Capital | Maintains | Buy | — |
| 20 Apr 2021 | Canaccord Genuity | Initiates | Buy | — |
| 9 Feb 2021 | National Securities Corporation | Initiates | Buy | — |
| 27 Jan 2021 | Aegis Capital | Maintains | Buy | — |
| 13 July 2020 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 June 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Sept 2019 | Ladenburg Thalmann | Initiates | Buy | — |
| 19 Nov 2015 | FBR Capital | Initiates | Outperform | — |
| 1 Oct 2015 | H.C. Wainwright | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ORMP appears on the weeks it earns a place.
ORMP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Oramed Pharmaceuticals, Inc. (ORMP) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 1.1×
- Price / sales
- 93.2×
- Price / book
- 0.6×
- EV / EBITDA
- −9.5×
Cheaper than 71% of US stocks
Cheaper than 4% of US stocks
Cheaper than 83% of US stocks
Cheaper than 84% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- 488.2%
- Gross margin
- —
- Operating margin
- 3766.2%
- Net margin
- 0.7%
Higher than 95% of US stocks
Higher than 99% of US stocks
Higher than 48% of US stocks
- Return on equity
- 74.2%
- Return on assets
- −3.4%
- Dividend yield
- 5.7%
Higher than 95% of US stocks
Higher than 34% of US stocks
Higher than 85% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ORMP vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Oramed Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about ORMP stock
How does Ticker Nerd's model rank ORMP?
As at 15 Aug 2026, Oramed Pharmaceuticals, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (83 of 100).
What is the ORMP stock forecast for 2030?
No analyst covering Oramed Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ORMP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.25 to $6.25 over the next 12 months.
How has ORMP stock performed over the past year?
Oramed Pharmaceuticals, Inc. returned +126.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Oramed Pharmaceuticals, Inc. do?
Oramed Pharmaceuticals Inc. is a biotechnology company focused on the research and development of oral drug delivery systems.
About Oramed Pharmaceuticals, Inc.
Oramed Pharmaceuticals Inc. is a biotechnology company focused on the research and development of oral drug delivery systems. The primary purpose of the company is to transform injectable treatments into oral forms, thereby aiming to enhance patient convenience and compliance. A notable highlight of Oramed's innovation is its proprietary Protein Oral Delivery (POD) technology, which facilitates the oral administration of proteins that traditionally require injections. This innovative approach has significant implications for therapeutics, particularly in areas like diabetes treatment, where oral insulin could potentially revolutionize disease management. Headquartered in Jerusalem, Israel, Oramed Pharmaceuticals Inc. holds a significant position in the healthcare sector, pushing forward the boundaries of medical treatment options through its cutting-edge research. Its development pipeline showcases the potential to reshape how chronic illnesses are managed, emphasizing the company's role as a pioneer in the oral delivery of biologics in the financial and healthcare markets.
CEO Mr. Nadav Kidron Esq. · United States · https://oramed.com